Engineered proteins that bind specific targets with high affinity. Bispecific antibodies engage two targets simultaneously, enabling novel mechanisms like T-cell redirection. AI is accelerating antibody humanization, affinity maturation, and developability optimization.
A 50/50 partnership worth up to $4.3B pairs Regeneron's antibody discovery platform with Telix's radiopharmaceutical manufacturing and global supply chain. The deal signals that biologics giants see targeted radiotherapy as the next frontier in oncology.
Apr 13, 2026 · 6 min read
In a landmark deal structure for AI drug discovery, Lilly commits a mid-eight-figure annual license fee to Chai Discovery for access to its biologics design foundation model. Separately, GSK pays $50M upfront to NOETIK for its oncology model. The era of AI-as-infrastructure-for-pharma is here.
Apr 12, 2026 · 7 min read
Biogen's tender offer for Apellis Pharmaceuticals adds Empaveli and Syfovre (combined ~$689M 2025 revenue) and a nephrology pipeline, diversifying beyond its slowing MS franchise. The deal signals complement-pathway biology is now worth blockbuster acquisition prices.
Mar 31, 2026 · 6 min read
RFdiffusion fine-tuned for de novo antibody design. Generates VHHs, scFvs, and full antibodies targeting user-specified epitopes. Experimentally validated with cryo-EM.
Suite for predicting 3D structures of antibodies (ABodyBuilder), nanobodies (NanoBodyBuilder2), and TCRs (TCRBuilder2) from sequence.